Telix Pharmaceuticals Limited (NASDAQ: TLX) today noticed its shares fall Wednesday. The company announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy (EBRT).
“EBRT”, reads this morning’s news release, “is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typically delivered by radiation oncologists who play a central role in managing cancer across multiple stages of the patient journey. The role of EBRT and radiation oncology in treating cancer could potentially be enhanced by integrating with therapeutic radiopharmaceuticals and precision diagnostics.”
Working with Varian, a key player in EBRT, Telix will explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment.
The first area of investigational focus is PSMA-PET1 imaging for prostate cancer radiotherapy patients. Telix and Varian aim to identify opportunities to utilize Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) and Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection)2 in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian’s Ethos adaptive radiotherapy), and monitoring responses to treatment.
TLX shares deducted 32 cents, or 2.4%, to $14.00.
